Back to Trials
NCT07073820PHASE2Recruiting

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Pfizer

Start Date

11/10/2025

Completion Date

7/18/2028

Summary

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Eligibility Criteria

Age Range: 18 years to No maximum

This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * do not have worsening or hospitalization for worsening PAH during the qualifying study. * not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH. * do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study. * not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem). * not currently prescribed or taking medicines called as GLP-1 agonist.

Interventions

DRUG

PF-07868489

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Pulmonary Hypertension

Locations

UC Davis Health Medical Center

Sacramento, California 95817

United States

UCSF Health St. Mary's Hospital

San Francisco, California 94117

United States

Heart and Vascular Center

San Francisco, California 94143

United States

University of Colorado Anschutz Medical Campus

Aurora, Colorado 80045

United States

Norton Hospital

Louisville, Kentucky 40202

United States

Norton Pulmonary Specialists

Louisville, Kentucky 40202

United States

Mount Sinai Hospital

New York, New York 10029

United States

Clinical Trials Unit at Eastowne Medical Office Building

Chapel Hill, North Carolina 27514

United States

Pulmonary Hypertension Clinical Trials Office at Eastowne

Chapel Hill, North Carolina 27514

United States

Pulmonary Specialty Clinic at Eastowne Medical Office Building

Chapel Hill, North Carolina 27514

United States

UNC Hospitals

Chapel Hill, North Carolina 27514

United States

Rhode Island Hospital

Providence, Rhode Island 02903

United States

Center for Advanced Lung Care

Providence, Rhode Island 02904

United States

Royal Prince Alfred Hospital

Camperdown, New South Wales 2050

Australia

Pulmonary Hypertension Research Queensland Pty Ltd

Auchenflower, Queensland 4066

Australia

HUB Hôpital Erasme

Brussels, 1070

Belgium

UZ Leuven

Leuven, 3000

Belgium

London Health Sciences Centre - University Hospital

London, Ontario N6A 5A5

Canada

London Health Sciences Centre

London, Ontario N6A 5W9

Canada

Guangdong Provincial People's Hospital

Guangzhou, Guangdong 510080

China

The Second Xiangya Hospital of Central South University

Changsha, Hunan 410011

China

Zhongda Hospital Southeast University

Nanjing, Jiangsu 210009

China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality 200433

China

Vseobecna fakultni nemocnice v Praze

Prague, 12808

Czechia

CHRU de Brest

Brest, Finistère 29200

France

Centre Hospitalier Universitaire de Saint-Etienne, Hôpital Nord

Saint-Priest-en-Jarez, 42055

France

Thoraxklinik-Heidelberg gGmbH

Heidelberg, Baden-Wurttemberg 69126

Germany

Universitätsklinikum Regensburg

Regensburg, Bavaria 93053

Germany

Universitaetsklinikum Giessen und Marburg GmbH

Giessen, Hesse 35392

Germany

Universitätsmedizin Greifswald

Greifswald, Mecklenburg-Vorpommern 17475

Germany

Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

Dresden, Saxony 01307

Germany

University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"

Chaïdári, Attica 12461

Greece

Onassis Hospital

Kallithea, Attica 17674

Greece

AHEPA University General Hospital of Thessaloniki

Thessaloniki, Central Macedonia 54636

Greece

Fondazione IRCCS San Gerardo dei Tintori

Monza, Monza E Brianza 20900

Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, 27100

Italy

Kobe University Hospital

Kobe, Hyōgo 650-0017

Japan

St. Marianna University Hospital

Kawasaki, Kanagawa 216-8511

Japan

Tohoku University Hospital

Sendai, Miyagi 980-8574

Japan

National Hospital Organization Okayama Medical Center

Okayama, 701-1192

Japan

Gachon University Gil Medical Center

Incheon, Incheon-gwangyeoksi [incheon] 21565

South Korea

Seoul National University Hospital

Seoul, Seoul-teukbyeolsi [seoul] 03080

South Korea

Severance Hospital, Yonsei University Health System

Seoul, Seoul-teukbyeolsi [seoul] 03722

South Korea

Samsung Medical Center

Seoul, Seoul-teukbyeolsi [seoul] 06351

South Korea

Hospital Universitario Marques de Valdecilla

Santander, Cantabria 39008

Spain

Hospital Universitario La Paz

Madrid, Madrid, Comunidad de 28046

Spain

Hospital Universitario 12 de Octubre

Madrid, 28041

Spain

Hammersmith Hospital

London, Greater London W12 0HS

United Kingdom